Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Paracetamol, Guaifenesin, and Phenylephrine Tablet vs Vicks Active SymptoMax Plus
NCT03213353Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acetaminophen, guaifenesin and phenylephrine in common cold (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Peak Plasma Concentration at 12 hours, Area under the plasma concentration-vs.-time curve from start to last measurable concentration at 12 hours and 6 more. Started Jul 2017; status: completed.
02
Drugs
acetaminophenguaifenesinphenylephrine
03
Conditions
common cold
Beyond the preview
Go deeper on NCT03213353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213353.